The evolution of aldosterone antagonists

Molecular and Cellular Endocrinology

Volumn 217, Issue 1-2, 2004, Pages 27-31

  Garthwaite, Susan M ^a   McMahon, Ellen G ^a,b  

^a PFIZER INC   (United States)

^b Cardiovascular Diseases Research   (United States)

Author keywords

Aldosterone; Aldosterone antagonists; Aldosterone blockers; Eplerenone; Selectivity; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; SPIRONOLACTONE; STEROID RECEPTOR;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOCRINE DISEASE; GYNECOMASTIA; HUMAN; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; MASTALGIA; MENSTRUATION DISORDER; MOLECULE; NONHUMAN; PATIENT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; GYNECOMASTIA; HISTORY, 20TH CENTURY; HUMANS; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE;

EID: 2342592636     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.005     Document Type: Conference Paper

References (39)

1. Abshagen U., et al. Effect of enoterohepatic circulation on the pharmacokinetics of spironolactone in man. Naunyn-schmiedeberg's Arch. Pharmacol. 300:1977;281-287
2. Brilla C., Pick R., Tan L., Janicki J., Weber K. Remodeling of the right and left ventricles in experimental hypertension. Circ. Res. 67:1990;1355-1364
3. Carpenter C., Davis J.O., Ayers C.R. Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion. J. Clin. Invest. 40:1961;26-2042
4. Cella J., Tweit R. Steroidal aldosterone blockers. II. J. Org. Chem. 24:1959;1109-1110
5. Cella J., Brown E.A., Burtner R.R. Steroidal aldosterone blockers. I. J. Org. Chem. 24:1959;743-748
6. Cook C.S., Berry L.M., Kim D.H., Burton E.G., Hribar J.D., Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A and CYP3A5. Drug Met. Dispos. 30:2002;1344-1351
7. Corval P., Michaud A., Menard J., Freifeld M., Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 104:1979;1194-1200
8. Cutler G.B., Pita J.C., Rifka S.M., Menard R.H., Sauer M.A., Loriaux D.L. SC-25152: A potent mineralocorticoid antagonist with reduced affinity for the 5α-dihydrotestosterone receptor of human and rat prostate. J. Clin. Endocrinal. Metab. 47:1978;171-175
9. Cutler G.B., Sauer M.A., Loriaux D.L. SC-25152: A potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone. J. Pharmacol. Exp. Ther. 209:1979;144-146
10. Davis J.O., Freeman R.H. Mechanisms regulating renin release. Physiol. Rev. 56:1976;1-56
11. deGasparo M., Joss U., Ramjoue H.P., Whitebread S.E., Haenni H., Schenkel L., Kraehenbuehl C., Biollaz M., Grob J., Schmidlin J., Wieland P., Wehrli H.U. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharm. Exp. Ther. 240:1987;650-656
12. Delyani J.A., Robinson E.L., Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 281:2001a;H647-H654
13. Delyani J.A., Rocha R., Cook C.S., Tolbert D.S., Levin S., Roniker B., Workman D.L., Sing Y.-L., Whelihan B. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 19(3):2001b;185-200
14. Fanestil D.D. Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochem. Pharmacol. 17:1968;2240-2242
15. Flack J.M., Oparil S., Pratt J.H., Roniker B., Garthwaite S., Kleiman J.H., Yang Y., Krause S.L., Workman D., Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J. Am. Coll. Cardiol. 41:2003;1148-1155
16. Funder J., Feldman D., Highland E., Edelman I. Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem. Pharmacol. 23:1974;1493-1501
17. Greenblatt D.J., Koch-Weser J. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. J. Am. Med. Assoc. 225:1973;40-43
18. Huffman D.H., Kampmann J.P., Hignite C.E., Azarnoff D.L. Gynecomastia induced in normal males by spironolactone. Clin. Pharmacol. Ther. 24:1978;465-473
19. Hutchinson J.H., Porter G.A. Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder. Res. Comm. Chem. Path. Pharm. 1(3):1970;363-369
20. Kagawa C.M., et al. Action of new steroids blocking effects of aldosterone and desoxycorticosterone on salt. Science. 126:1957;1015-1016
21. Karim A. Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab. Rev. 8(1):1978;151-188
22. Krum H., Nolly H., Workman D., He W., Roniker B., Krause S., Fakouhi K. Addition of eplerenone to ACE inhibition or angiotensin blockade in hypertensive patients. Hypertension. 40:2002;117-123
23. Landau R.L., Bergenstal D.M., Lugibihl A.B., Kascht M.E. The metabolic effects of progesterone in man. J. Clin. Endocrinol. Metab. 15:1952;1194-1215
24. McMahon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1:2001;190-196
25. Overdiek H.W. The metabolism and biopharmaceutics of spironolactone in man. Drug Metab. Interact. 5:1987;273-302
26. Pitt B., Zannad F., Remme W., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Eng. J. Med. 341(10):1999;709-715
27. Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Neaton J., Rniker B., Hurley S., Burns D., Bittman R., Kleiman J. The EPHESUS Trial: eplerenone in patients with heat failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc. Drugs Ther. 15:2001;79-87
28. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 348(14):2003;1309-1321
29. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak N., Kekec B.K., Blomme E.A.G., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. 283:2002;H1802-H1810
30. Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc. Soc. Exp. Biol. Med. 104:1960;212-213
31. Simpson S.A., Tait J.F., Wettstein A., Neher R., Von Euw V.J., Reichstein T. Isolierung eines neuen kristallisierten hormons aus nebennieren mit besonderer hoher wirksamkeit auf den mineralstoff wechsel. Experientia. 9:1953;33-38
32. Sturtevant F.M. Prevention of adrenal-regeneration hypertension by an aldosterone-blocker. Endocrinology. 64:1959;299-300
33. Suzuki G., Morita H., Mishima T., Sharov V.G., Todor A., Tanhehco E.J., Rudolph A.E., McMahon E.G., Goldstein S., Sabbah H.N. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 106:2002;2967-2972
34. Tolbert D.S., Reid S.E., Roniker B. Satefy, tolerability and pharmacokinetics of eplerenone, a selective aldosterone blocker. Pharmacokinetics. 22(10):2002;1331. (abstract)
35. Ulmann A., Bertagna C., LeGo A., Husson J.M., Tache A., Sassano P., Menard J., Corvol P. Assessment of the antimineralocorticoid effect of RU 28 318 in healthy men with induced exogenous and endogenous hyper-mineralocorticism. Eur. J. Clin. Pharmacol. 28:1985;531-535
36. United States Patent Office. 3, 013, 012, 1960. Alkanoylthio-17α- carboxyethyl-17β-hydroxyandrosten-3-one lactones. Ser. no. 77, 517.
37. Weinberger M., Roniker B., Krause S., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension. Am. J. Hypertens. 15(8):2002;709-716
38. White W.B., Duprez D., St. Hillaire R., Krause S., Roniker B., Juse-Hamilton J., Weber M.A. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 41:2003a;1021-1026
39. White W.B., Carr A.A., Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. 92:2003b;38-42